KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

By E. Massarelli, M. Varella-Garcia, Ximing Tang, A. C. Xavier, N. Ozburn, Diane D Liu, B. N. Bekele, R. Herbst, I. Wistuba. Clinical Cancer Research, 2007

612 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/78afa263e065b4410472d99b3695a050d6a5d242

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. B. Chan
2. Gad Getz
3. M. Bahar
4. B. Hughes
5. D. Kim
6. Hyun Joon Kim
7. Kevin P. White

In Oncology

1. Gad Getz
2. R. Weichselbaum

In Pulmonary and Respiratory Medicine

1. B. Chan
2. B. Hughes

Citations in the corpus

• Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies (2023, background): “304 While the development of the direct RAS inhibitors has been proven challenging due to the nature of RAS protein, ongoing research and clinical trials are exploring strategies and therapies to effectively target KRAS -mutant tumors.”
• Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas (2014, background): “lung adenocarcinomas), as well as resistance to cetuximab in colon cancer (39).”
• Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. (2015, background): “Thus upfront tumour interrogation for predictive biomarkers has now become standard and if EGFR demonstrates an activating mutation, then EGFR TKIs should be given as first-line therapy.”